In the SK-Hep-1-derived xenograft model, the CXCR6 antagonist, SBI-457, modestly reduced tumor burden alone and non-significantly in combination with sorafenib while attenuating sorafenib-induced β-catenin upregulation. This evidence concerns the gene CXCR6 and neoplasm.